The Quotient Therapeutics team (L-R): acting COO Scott Hayton, head of genetics and target discovery Caroline Fox, president Jacob Rubens, head of platform Simon Brunner, and CEO Geoff von Maltzahn (Credit: Quotient Therapeutics)

Flag­ship launch­es first UK-based start­up to un­cov­er genes that make cells vul­ner­a­ble or re­sis­tant to dis­ease

A new biotech start­up be­lieves that ge­net­ic di­ver­si­ty found among the tril­lions of cells that com­prise an in­di­vid­ual per­son could hold the keys to new …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.